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#Appendix 1.
Dystonia is a neurological disorder characterized by sustained or intermittent muscle contractions causing abnormal movements and
postures, often occurring in absence of any structural brain abnormality. Psychiatric comorbidities, including anxiety, depression, obses-
sive-compulsive disorder and schizophrenia, are frequent in patients with dystonia. While mutations in a fast-growing number of genes
have been linked to Mendelian forms of dystonia, the cellular, anatomical, and molecular basis remains unknown for most genetic
forms of dystonia, as does its genetic and biological relationship to neuropsychiatric disorders. Here we applied an unbiased systems-
biology approach to explore the cellular specificity of all currently known dystonia-associated genes, predict their functional relation-
ships, and test whether dystonia and neuropsychiatric disorders share a genetic relationship. To determine the cellular specificity of
dystonia-associated genes in the brain, single-nuclear transcriptomic data derived from mouse brain was used together with expression-
weighted cell-type enrichment. To identify functional relationships among dystonia-associated genes, we determined the enrichment of
these genes in co-expression networks constructed from 10 human brain regions. Stratified linkage-disequilibrium score regression was
used to test whether co-expression modules enriched for dystonia-associated genes significantly contribute to the heritability of anxiety,
major depressive disorder, obsessive-compulsive disorder, schizophrenia, and Parkinson’s disease. Dystonia-associated genes were signifi-
cantly enriched in adult nigral dopaminergic neurons and striatal medium spiny neurons. Furthermore, 4 of 220 gene co-expression
modules tested were significantly enriched for the dystonia-associated genes. The identified modules were derived from the substantia
nigra, putamen, frontal cortex, and white matter, and were all significantly enriched for genes associated with synaptic function. Finally,
we demonstrate significant enrichments of the heritability of major depressive disorder, obsessive-compulsive disorder and schizophrenia
within the putamen and white matter modules, and a significant enrichment of the heritability of Parkinson’s disease within the substan-
tia nigra module. In conclusion, multiple dystonia-associated genes interact and contribute to pathogenesis likely through dysregulation
of synaptic signalling in striatal medium spiny neurons, adult nigral dopaminergic neurons and frontal cortical neurons. Furthermore,
the enrichment of the heritability of psychiatric disorders in the co-expression modules enriched for dystonia-associated genes indicates
that psychiatric symptoms associated with dystonia are likely to be intrinsic to its pathophysiology.
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Introduction
The term dystonia defines a heterogeneous family of
hyperkinetic movement disorders unified by their
clinical manifestations, which include sustained or intermit-
tent muscle contractions causing abnormal, often
repetitive, movements, postures, or both (Albanese et al.,
2013). While dystonia can occur as the consequence of
both focal and degenerative brain lesions, most commonly
affecting the basal ganglia (Bhatia and Marsden, 1994)
or cerebellum (Batla et al., 2015), most patients with
dystonia have normal neuroimaging findings and pathologic-
al studies have consistently shown the absence of even
subtle structural abnormalities (Sharma, 2019). Thus, like
epilepsy, dystonia has a dual nature, presenting both as
the of specific brain lesions and as a discrete disease entity.
The aetiology of dystonia occurring in the absence of struc-
tural abnormalities is unknown in most cases. Pathogenic
mutations in a fast-growing number of genes have been linked
to Mendelian forms of ‘idiopathic dystonia’ and appear to be
an important cause of dystonia, especially in cases with paedi-
atric onset of symptoms and/or strong family history (Balint
et al., 2018). Clinically, mutations in these dystonia-associated
genes (hereafter termed DYT genes) produce a range of pheno-
types, including isolated (dystonia occurring alone), combined
(dystonia associated with myoclonus or parkinsonism) and par-
oxysmal forms of the condition (intermittent attacks of dys-
tonia with normal interictal neurological examination) (Marras
et al., 2016; Lohmann and Klein, 2017; Zhang et al., 2019),
with a subset of genes capable of producing multiple clinical
presentations (Friedman et al., 2016; Carecchio et al., 2017;
Zech et al., 2017; Balint et al., 2019).
Genetic discoveries played a key role in conclusively pushing
dystonia into the realm of neurological disorders after decades
of controversy during which dystonia was considered by many
to be a psychiatric condition (Lesser and Fahn, 1978). Still, dys-
tonia not only affects motor function, but presents with add-
itional psychiatric symptoms in 50–90% of patients with
dystonia, including both patients with sporadic and monogenic
forms (Stamelou et al., 2012; Peall et al., 2013, 2015;
Zurowski et al., 2013; Conte et al., 2016). These symptoms
range from depression and anxiety (Lencer et al., 2009;
Fabbrini et al., 2010; Steinlechner et al., 2017) to obsessive
compulsive disorder (Voon et al., 2010; Barahona-Correa
et al., 2011) and psychosis (Brashear et al., 2012; Vijiaratnam
et al., 2018; Timmers et al., 2019), with depression and anxiety
disorders being the most common (Smit et al., 2016; Berman
et al., 2017). Psychiatric co-morbidities often precede the onset
of motor symptoms (Moraru et al., 2002; Lencer et al., 2009)
and have a profound impact on dystonia patients’ quality of
life (Smit et al., 2016; Eggink et al., 2019).
These observations raise the question of whether psychiatric
symptoms are intrinsic to the neurobiology of dystonia, a ques-
tion that is hard to address as the physiological and pathogenic
roles of DYT genes are known only for a minority of genes.
For instance, it is well established that the genes associated
with forms of dystonia responsive to dopamine replacement
(i.e. DOPA-responsive dystonias) are all involved in the synthe-
sis and metabolism of dopamine in nigral dopaminergic neu-
rons (Ng et al., 2015; Ribot et al., 2019). However, little is
known about the biological function of many of the other
DYT genes and how they contribute to disease pathogenesis.
The recent progress in our understanding of the genetic
architecture of both dystonia and neuropsychiatric diseases,
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together with the increased availability of brain-related func-
tional genomic annotations, offers a unique opportunity to
robustly examine the relationship between these conditions.
More specifically, whole-exome sequencing efforts have
resulted in the identification of several novel monogenic
causes of dystonia (described above), and genome-wide asso-
ciation studies (GWAS) for schizophrenia (Pardinas et al.,
2018), obsessive-compulsive disorder [International
Obsessive Compulsive Disorder Foundation Genetics
Collaborative (IOCDF-GC) and OCD Collaborative
Genetics Association Studies (OCGAS), 2018], anxiety
(Otowa et al., 2016), and major depressive disorder (Wray
et al., 2018) have provided an increasingly long list of risk
loci.
Thus, in this study we applied a comprehensive systems
biology approach to explore the following unanswered ques-
tions: (i) which brain cells are most relevant to the pathogen-
esis of monogenic dystonias? (ii) do DYT genes interact and
coalesce in shared cellular and molecular pathways? And if
yes, in which brain regions and/or cells does this happen?
and (iii) is there a genetic relationship between dystonia and
neuropsychiatric disorders suggesting a shared neurobio-
logical basis? Setting aside the DYT genes contributing to
forms of DOPA-responsive dystonia, our analyses suggest
that multiple dystonia-genes interact and play a fundamental
role in the pathogenesis of dystonia likely through dysregula-
tion of synaptic signalling in striatal medium spiny neurons
(MSNs) and frontal cortex pyramidal neurons. Furthermore,
we show that DYT genes enrich within co-expression mod-
ules that also enrich for the heritability of neuropsychiatric
disorders, suggesting that the psychiatric symptoms associ-
ated with dystonia are intrinsic to its pathophysiology.
Materials and methods
Definition of idiopathic dystonia-
related genes
Many heterogeneous monogenic disorders can present with dys-
tonia, often amongst other neurological abnormalities, as a
symptom of structural or degenerative lesions of the basal gan-
glia. From a biological point of view, this list includes very dif-
ferent conditions, including several metabolic disorders (i.e.
organic acid, mitochondrial, and lysosomal storage disorders),
brain metal accumulation disorders, and several neurodegenera-
tive conditions (Fung et al., 2013). Herein, we focused our ana-
lysis on monogenic dystonias that occur in the absence of any
brain structural abnormality (i.e. idiopathic dystonia), hypothe-
sizing that this group may share similar biological mechanisms,
different from those of dystonias secondary to brain structural
changes.
The Movement Disorders Society (MDS) has recently pro-
vided a list of the established genes clinically associated with
prominent dystonia (Marras et al., 2016). From this list, we
included only those genes that when mutated cause prominent
dystonia in the absence of imaging or neuropathological evi-
dence of structural or degenerative abnormalities (as reported
by at least two independent groups). Therefore, all DYT genes
systematically associated with a radiological or pathological
phenotype of basal ganglia injury, metal accumulation (i.e. iron,
manganese, copper and calcium) or overt neurodegeneration
(e.g. TAF1 and other genes associated with degenerative com-
plex dystonia-parkinsonism) were excluded. Furthermore, we
included all DYT genes regardless of their most commonly asso-
ciated clinical phenotype (i.e. isolated, combined and paroxys-
mal dystonia). To ensure our list of DYT genes was up to date,
we complemented the MDS list with the additional confirmed
isolated and combined dystonia genes (ANO3 and KMT2B)
included in the most recently published review on dystonia
(Balint et al., 2018). Furthermore, we included four additional
genes for which an established pathogenic role in dystonia has
only been recently demonstrated, namely KCTD17 (Mencacci
et al., 2015; Graziola et al., 2019; Marce-Grau et al., 2019),
HPCA (Charlesworth et al., 2015; Atasu et al., 2018),
SLC18A2 (Rilstone et al., 2013; Rath et al., 2017), DNAJC12
(Anikster et al., 2017; Veenma et al., 2018). As for paroxysmal
dystonias, we included the confirmed genes listed in the most re-
cent review on the topic (Zhang et al., 2019). The confirmed
DYT genes included in the analysis are listed in Table 1.
Unconfirmed DYT genes (i.e. CIZ1, COL6A3, RELN) were
not included in the analysis.
Expression-weighted cell-type
enrichment
Expression-weighted cell-type enrichment (EWCE) (see ‘URLs’
section) was used to determine whether DYT genes have higher
expression within particular brain-related cell types than would
be expected by chance (Skene and Grant, 2016). As our input
we used (i) the list of DYT genes as defined above; and (ii) spe-
cificity values calculated for level 1 cell types from two inde-
pendent single-cell/nuclei RNA-sequencing datasets. These
datasets included (i) mouse single-cell RNA sequencing from the
Karolinska superset, which includes cell types from the neocor-
tex, hippocampus, hypothalamus, striatum and midbrain (see
‘URLs’ section) (Skene et al., 2018); and (ii) human single-nuclei
RNA sequencing from the substantia nigra (Agarwal et al., sub-
mitted for publication, accessed via GEO; GEO accession:
GSE140231; see ‘URLs’ section). Specificity values (i.e. propor-
tion of total expression of a gene in one cell type compared to
all others) for the mouse Karolinska superset had been previous-
ly published (Skene et al., 2018). For the GEO-derived dataset,
however, the cell-type specificity of each gene was estimated
using substantia nigra-derived read count values together with
the ‘generate.celltype.data()’ function of the EWCE package.
The generated specificity matrix is available online via the
MarkerGenes package (see ‘URLs’ section). EWCE with the tar-
get list was run with 100 000 bootstrap replicates, which were
sampled from a background list of expressed genes (when using
mouse-derived data, this background list excluded all genes
without a 1:1 mouse: human orthologue). We additionally con-
trolled for transcript length and GC content biases by selecting
bootstrap lists with comparable properties to the target list.
Data are displayed as standard deviations from the mean, and
any values 5 0, which reflect a depletion of expression, are dis-
played as 0. P-values were corrected for multiple testing using
the Benjamini-Hochberg method over all cell types in each
dataset.
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Weighted gene co-expression
analysis
We generated gene co-expression networks (GCNs) for CNS tis-
sue-specific transcriptomic data generated by the UK Brain
Expression Consortium (UKBEC) (Ramasamy et al., 2014) and
Genotype-Tissue Expression Consortium (GTEx) (GTEx
Consortium, 2015) (Version 6; www.gtexportal.org). In total,
57 gene-level expression datasets across an equal number of tis-
sues were used with the weighted gene co-expression network
analysis (WGCNA) R package with k-means adjustment to gen-
erate tissue-specific networks (Langfelder and Horvath, 2008;
Langfelder et al., 2008; Botia et al., 2017). For each tissue, a
‘signed’ GCN was constructed by creating a signed Topological
Table 1 List of dystonia-associated genes included in the analysis
Dystonia
classification
Main dystonic phenotype Gene Inheritance Locus Other common clinical presentations/addition-
al clinical features
Combined dystonia Dopa-responsive dystonia-
parkinsonism
DDC AR None DD, oculogyric crisis, truncal hypotonia, dysautono-
mia, ptosis
DNAJC12 AR None DD, intellectual disability, HPA
GCH1 AD and AR DYT5 DD, hypotonia, spasticity and HPA in in bi-allelic muta-
tion carriers
PTS AR None DD, oculogyric crisis, truncal hypotonia, dysautono-
mia, seizures, HPA
QDPR AR None DD, oculogyric crisis, truncal hypotonia, dysautono-
mia, seizures, HPA
SLC18A2 AR None DD, truncal hypotonia, dysautonomia
SLC6A3 AR None DD, oculogyric crisis, truncal hypotonia, bulbar
dysfunction
SPR AR None DD, oculogyric crisis, truncal hypotonia,
dysautonomia
TH AR DYT5b DD, oculogyric crisis, truncal hypotonia, dysautono-
mia, ptosis
Dystonia-chorea-myoclonus ADCY5 AD and AR None Episodic hyperkinesias triggered by sleep
Generalized dystonia with prom-
inent cranial involvement
KMT2B AD DYT28 Intellectual disability, short stature
Myoclonus-dystonia KCTD17 AD DYT26 Mild motor DD
SGCE AD DYT11 Psychiatric co-morbidities (anxiety, obsessive compul-
sive disorder, alcohol addiction)
Generalized dystonia with prom-
inent laryngeal dystonia
TUBB4A AD DYT4 Hypomyelination with atrophy of basal ganglia and
cerebellum (H-ABC)
Generalized dystonia-
parkinsonism
PRKRA AR DYT16 None
Rapid-onset dystonia
parkinsonism
ATP1A3 AD DYT12 Alternating hemiplegia of childhood, Cerebellar ataxia,
areflexia, pes cavus, optic atrophy, and sensori-
neural hearing loss (CAPOS) syndrome, paroxys-
mal limb dystonia
Isolated dystonia Adult-onset cranio-cervical
dystonia
ANO3 AD DYT24 Subcortical myoclonus, prominent dystonic tremor
GNAL AD and AR DYT25 None
Early-onset generalized dystonia HPCA AR DYT2 Learning disabilities, DD
THAP1 AD and AR DYT6 None
TOR1A AD DYT1 Severe arthrogryposis in bi-allelic mutation carriers
Paroxysmal dystonia Paroxysmal exercise-induced
dystonia
SLC2A1 AD DYT9 or DYT18 GLUT1-deficiency syndrome (DD, spasticity, micro-
cephaly, ataxia, epilepsy)
Paroxysmal kinesigenic dystonia KCNA1 AD n/a Paroxysmal ataxia with interictal myokymia
PRRT2 AD DYT10 or DTY19 Benign familial infantile epilepsy, hemiplegic migraine,
paroxysmal torticollis of infancy
SCN8A AD None Benign familial infantile seizures, early infantile epilep-
tic encephalopathy
Paroxysmal non-kinesigenic
dystonia
KCNMA1 AD None Epilepsy, DD, cerebellar ataxia
PNKD AD DYT8 None
Paroxysmal torticollis of infancy CACNA1A AD None Paroxysmal ataxia with interictal dystonia, hemiplegic
migraine, SCA6, early infantile epileptic
encephalopathy
Genes have been grouped by their overall dystonia classification and main dystonic phenotype. Within these groupings, genes are sorted alphabetically. AD = autosomal dominant;
AR = autosomal recessive; DD = developmental delay; HPA = hyperphenylalanaemia; SCA = spinocerebellar ataxia.
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Overlap Measure (TOM) matrix based on Pearson correlation.
Gene modules were created by hierarchical clustering based on
a 1-TOM dissimilarity matrix. The results of the initial hierarch-
ical clustering were post-processed using the k-means clustering
search method with 30 iterations. All co-expression networks
are available online via the CoExp website (www.rytenlab.com/
coexp/Run/Catalog/) or CoExpNets package (https://github.com/
juanbot/CoExpNets) to enable use with third-party software.
To assess module preservation within and between datasets
we performed a preservation analysis based on WGCNA using
the Z summary statistic to evaluate preservation (Langfelder
et al., 2011). As per Langfelder et al., if Z summary statistic 4
10, there is strong evidence of module preservation; if 25Z
summary statistic 5 10, there is weak to moderate evidence of
preservations; and finally, if Z summary statistic 5 2, there is
no evidence of preservation.
Gene modules were functionally annotated with gProfileR R
package using Gene Ontology (GO) database without
Electronic Inferred Annotations (EIA) and accounting for mul-
tiple testing with gSCS (Reimand et al., 2007). Additional func-
tional annotations for modules of interest were generated using
the web server SynGO (https://www.syngoportal.org/), which
provides an expert-curated resource for synapse function and
gene enrichment analysis (Koopmans et al., 2019). All gene set
enrichment analyses were performed using default settings, with
no annotation filters applied and a minimum gene count of
three for ontology terms to be included in the overrepresenta-
tion analysis.
Stratified linkage disequilibrium
score regression
Stratified linkage disequilibrium score regression (LDSC) (see
‘URLs’ section) (Finucane et al., 2015) was used to test whether
co-expression modules enriched for DYT genes significantly con-
tributed to the common single nucleotide polymorphism (SNP)
heritability of four neuropsychiatric disorders (anxiety, major de-
pressive disorder, obsessive compulsive disorder, and schizophre-
nia) and one neurodegenerative disorder (Parkinson’s disease)
(Table 2). Co-expression modules from UKBEC and GTEx were
downloaded using the CoExpNets package (see ‘URLs’ sec-
tion). As previously performed, modules were filtered to in-
clude only genes with module membership 5 0.5 (Reynolds
et al., 2019). Furthermore, gene coordinates were extended
by 100 kb upstream and downstream of their transcription
start and end site, in order to capture regulatory elements
that might contribute to disease heritability (Finucane et al.,
2018).
All annotations were constructed in a binary format (1 if the
SNP was present within the annotation and 0 if not), using all
SNPs with a minor allele frequency 4 5%. Annotations were
then added individually to the baseline model of 53 annotations
provided by Finucane et al. (version 1.2, see ‘URLs’ section),
comprising genome-wide annotations reflecting genetic architec-
ture. HapMap Project Phase 3 (HapMap3) (Altshuler et al.,
2010) SNPs and 1000 Genomes Project (Abecasis et al., 2012)
Phase 3 European population SNPs were used for the regression
and LD reference panels, respectively. The MHC region was
excluded from all analyses because of the complex and long-
range linkage disequilibrium patterns in this region. For all
stratified LDSC analyses, we report a one-tailed P-value (coeffi-
cient P-value) based on the coefficient z-score outputted by
stratified LDSC. A one-tailed test was used as we were only
interested in annotation categories with a significantly positive
contribution to trait heritability, conditional upon the baseline
model. Multiple test correction was performed within a net-
work. Thus, to account for multiple tests, the Bonferroni signifi-
cance threshold was set to 0.05 divided by the number of
modules for each co-expression network (four for UKBEC; three
for GTEx) and the number of GWASs run. Nominal enrich-
ments were defined as those enrichments that did not pass the
Bonferroni cut-off, but passed P50.05.
URLs
CoExp website, www.rytenlab.com/coexp/Run/Catalog/;
CoExpNets package, https://github.com/juanbot/CoExpNets;
EWCE, https://github.com/NathanSkene/EWCE; Human sub-
stantia nigra single-nuclei RNA sequencing, https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE140231; Karolinska sin-
gle-cell RNA sequencing superset, https://github.com/
NathanSkene/MAGMA_Celltyping; LDSC, https://github.com/
bulik/ldsc; baseline LDSC annotations, https://data.broadinsti
tute.org/alkesgroup/LDSCORE/; MarkerGenes, https://github.
com/RHReynolds/MarkerGenes.
Table 2 Summary of GWAS datasets
Disease First author, year Cases, n Controls, n Reference
Anxiety Otowa (2016) 7016 14 745 Otowa et al. (2016)
Major depressive disorder
(excluding 23andMe
contributions)
Wray (2018) 59 851 113 154 Wray et al. (2018)
Obsessive compulsive disorder IOCDF-GC (2017) 2688 7037 International Obsessive Compulsive
Disorder Foundation Genetics
Collaborative (IOCDF-GC) and OCD
Collaborative Genetics Association
Studies (OCGAS) (2018)
Parkinson’s disease (excluding
23andMe contributions)
Nalls (2019) 33 674
(18 618 proxy cases
from UK Biobank)
449 037 Nalls et al. (2019)
Schizophrenia Pardinas (2018) 40 675 64 643 Pardinas et al. (2018)
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Data availability
All co-expression networks are openly available online via
the CoExp website (www.rytenlab.com/coexp/Run/Catalog/
) or CoExpNets package (https://github.com/juanbot/
CoExpNets). Raw data used to generate the specificity ma-
trix derived from human substantia nigra single-nuclei
sequencing is openly available online at https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi? acc=GSE140231; the gener-
ated specificity matrix is openly available at https://github.
com/RHReynolds/MarkerGenes. The specificity matrix derived
from the Karolinska superset is openly available at https://github.
com/NathanSkene/MAGMA_Celltyping. Data used to generate
Figs 1, 2, 4–6 and Supplementary Figs 1–3 are available within the
Supplementary material.
Figure 1 Dystonia-associated genes are highly expressed in dopaminergic neurons and medium spiny neurons from mouse.
(A) Enrichment of dystonia-associated genes in level 1 cell types from the Karolinska superset was determined using EWCE. Standard deviations
from the mean indicate the distance of the mean expression of the target list from the mean expression of the bootstrap replicates. Asterisks de-
note significance at P5 0.05 after correcting for multiple testing with the Benjamini-Hochberg method over all level 1 cell types. Numerical
results are reported in Supplementary Table 1. (B) Plot of specificity values for all dystonia-associated genes within adult nigral dopaminergic neu-
rons and medium spiny neurons (level 1 cell types from the Karolinska single-cell RNA-sequencing superset). Specificity values were derived
from Skene et al. (2018) who calculated specificity by dividing the mean expression of a gene in one cell type by the mean expression in all cell
types. In other words, specificity is the proportion of a gene’s total expression attributable to one cell type, with a value of 0 meaning a gene is
not expressed in that cell type and a value of 1 meaning that a gene is only expressed in that cell type. In both plots, cell types are coloured by
the overall class they belong to (e.g. astrocyte, neuron, oligodendrocyte, etc.).
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Results
Dystonia genes are highly and
specifically expressed in midbrain
dopaminergic and striatal medium
spiny neurons
In the first instance, we wanted to study the cellular specifi-
city of DYT genes across a broad range of brain regions,
with the aim of identifying the cell types most likely involved
in primary pathology. Using EWCE analysis and single-cell
gene expression profiling of the mouse brain (Karolinska
Institute brain superset from the Linnarsson group), which
included cell types from the neocortex, hippocampus, hypo-
thalamus, striatum and midbrain, we demonstrated that
DYT genes are significantly enriched in two cell types, name-
ly adult nigral dopaminergic neurons [false discovery rate
(FDR)-adjusted P-value 5 0.00001] and striatal MSNs
(FDR-adjusted P = 0.00156; Fig. 1A and Supplementary
Table 1).
The enrichment within adult nigral dopaminergic neurons
was largely driven by genes responsible for forms of dys-
tonia responsive to dopaminergic therapies (i.e. DOPA-re-
sponsive dystonias) (Ng et al., 2015). In fact, we noted that
SLC6A3, SLC18A2, TH, DDC, and GCH1, had the highest
specificity values in adult nigral dopaminergic neurons
(Fig. 1B and Supplementary Table 1).
ANO3, ADCY5, GNAL, and KCTD17 were the genes
with the highest specificity values in striatal MSNs. Amongst
these, ADCY5 and GNAL had specificity values more than
4-fold higher in MSNs than in other cell types, indicating al-
most exclusive expression in this cell type (Supplementary
Fig. 1 and Supplementary Table 1). While some of the genes
driving this enrichment have an established function in
MSNs (i.e. GNAL and ADCY5 are involved in striatal
dopaminergic and adenosinergic post-receptor signalling)
(Goodchild et al., 2013), ANO3 and KCTD17 have not
been studied in this context and their physiological role in
MSNs is currently unknown.
To ensure our results were robust to species differences,
we performed EWCE using single-nuclei gene expression
profiling from the human substantia nigra (Agarwal et al.,
submitted for publication, accessed via GEO; GEO acces-
sion: GSE140231; see ‘URLs’ section). We found that DYT
genes are significantly enriched in human dopaminergic neu-
rons (FDR-adjusted P-value 5 0.00001), confirming the en-
richment observed using mouse-derived single-cell data
(Fig. 2A and Supplementary Table 2). As in mouse dopa-
minergic neurons, SLC6A3, SLC18A2, TH, DDC, and
GCH1 had the highest specificity values in human dopamin-
ergic neurons (Fig. 2B and Supplementary Table 2) and, in
general, there was a strong positive correlation between
DYT gene specificity values in dopaminergic neurons derived
from mouse and human data (spearman’s rho = 0.85; P-
value 5 0.001; Supplementary Fig. 2).
Gene co-expression network
analysis identifies dystonia-enriched
modules
Commonalities in the cellular specificity of DYT genes sug-
gested the possibility that a subset of DYT genes may be
functionally related. However, EWCE analysis was based on
cell-specific gene expression data derived from mouse and
did not consider correlations in gene expression. Co-expres-
sion networks have proven to be an efficient means of iden-
tifying hidden functional relationships between genes of
interest (Oldham et al., 2008; Kelley et al., 2018). Thus, to
explore the possibility that a subset of DYT genes are func-
tionally related, we tested for the enrichment of DYT genes
within co-expression networks generated from 10 regions of
the human brain using transcriptomic data from UKBEC
(Ramasamy et al., 2014). Brain regions included: cerebellar
cortex, frontal cortex, hippocampus, inferior olivary nucleus,
occipital cortex, putamen (dissected at the level of the anter-
ior commissure), substantia nigra, temporal cortex, thalamus
and intralobular white matter.
Amongst the 220 gene co-expression modules tested, we
identified four modules in which DYT genes were signifi-
cantly enriched (FDR-adjusted P-value 5 0.05;
Supplementary Table 3). These four modules derived from
the substantia nigra (‘cyan’ module), putamen (‘cyan’ mod-
ule), frontal cortex (‘lightyellow’ module) and white matter
(‘blue’ module) networks. No enrichment of DYT genes was
observed in any of the other brain regions. To replicate these
findings, we tested for enrichment of DYT genes in co-ex-
pression networks generated using transcriptomic data from
the GTEx Project; only co-expression networks derived from
frontal cortex, putamen and substantia nigra were used.
Amongst the co-expression modules tested, DYT genes
enriched in three modules: frontal cortex ‘turquoise’ module,
putamen ‘blue’ module and substantia nigra ‘darkorange2’
module.
The overlap of DYT genes with the substantia nigra ‘cyan’
module was driven by seven DYT genes (GCH1, TH,
SLC6A3, DNAJC12, DDC, SLC18A2, PTS; FDR-adjusted
P = 0.0409) (Fig. 3A). This finding was replicated using
GTEx-derived co-expression networks, with a significant en-
richment of DYT genes in the substantia nigra ‘darkorange2’
module (FDR-adjusted P = 0.005) driven by an overlapping
set of six genes, namely GCH1, TH, SLC6A3, DDC,
SLC18A2 and PTS. Importantly, mutations in all DYT
genes enriched in these modules cause DOPA-responsive
dystonias and are well known to be functionally related to
dopamine synthesis and/or metabolism.
The most significant enrichment of DYT genes was
detected in a putamen gene co-expression module. Of the 28
DYT genes tested, eight overlapped with the ‘cyan’ module
in this tissue (ADCY5, ANO3, KCTD17, HPCA, PRRT2,
SCN8A, KCNA1, CACNA1A; FDR-adjusted P = 0.0001)
(Fig. 3B). This module included established cellular markers
of MSNs, including DRD1, DRD2, ADORA2A and
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PPP1R1B, indicating the module captures the expression
signature of these neurons. Again, this finding was sup-
ported by replication in GTEx-derived co-expression net-
works (putamen ‘blue’ module; FDR-adjusted P = 0.026),
with the enrichment driven by an overlapping set of six
DYT genes (ADCY5, KCTD17, HPCA, PRRT2, and
CACNA1A).
Significant enrichment of DYT genes was also detected in the
white matter ‘blue’ module (overlap of eight genes, PRRT2,
PNKD, SCN8A, KCNA1, ATP1A3, ANO3, KCTD17,
HPCA; FDR-adjusted P = 0.0203) and the ‘light-yellow’ frontal
cortex module (overlap of six genes, ANO3, GNAL,
KCTD17, HPCA, KCNMA1, CACNA1A; FDR-adjusted
P = 0.0203). Both modules were predicted to be expression sig-
natures of cortical pyramidal neurons. Where analysis was pos-
sible due to data availability (white matter tissue is not
available in GTEx), we noted that once again the findings in
frontal cortex were replicated in GTEx-derived co-expression
networks (frontal cortex ‘turquoise’ module; P = 0.0289).
Functional annotation showed that all four UKBEC dys-
tonia-linked modules were significantly enriched for genes
associated with neuronal synaptic transmission (putamen
‘cyan’ module, corrected P = 3.44  10–8; white matter
‘blue’ module P = 3.4  10–52; frontal cortex ‘lightyellow’
module, P = 9.82  10–7; substantia nigra cyan module,
P = 0.0247). Furthermore, in the case of both the ‘blue’ and
‘lightyellow’ modules we found significant enrichment of
terms relating to neurodevelopment, namely neuron projec-
tion development (white matter ‘blue’ module,
P = 4.96  10–26) and nervous system development (frontal
cortex ‘lightyellow’ module, nervous system development,
P = 1.14  10–5). Finally, in the case of the ‘cyan’ putamen
module, the most over-represented terms related to metal
ion transmembrane transport, indicating an enrichment of
genes coding for ion channels.
To investigate the significance of these modules further,
we sought to identify whether the enrichment of genes relat-
ing to synaptic transmission was driven by genes involved in
postsynaptic as compared to presynaptic structures. To ad-
dress this question, we checked for enrichment of genes that
have been reliably associated with a specific synaptic struc-
ture using the recently released SynGO database (Koopmans
Figure 2 Dystonia-associated genes are highly expressed in human dopaminergic neurons. (A) Enrichment of dystonia-associated
genes in level 1 cell types from human-derived substantia nigra single-nuclei RNA-sequencing data was determined using EWCE. Standard devia-
tions from the mean indicate the distance of the mean expression of the target list from the mean expression of the bootstrap replicates.
Asterisks denote significance at P5 0.05 after correcting for multiple testing with the Benjamini-Hochberg method over all level 1 cell types.
Numerical results are reported in Supplementary Table 2. (B) Plot of specificity values for all dystonia-associated genes within dopaminergic neu-
rons (level 1 cell type from human-derived substantia nigra single-nuclei RNA-sequencing data). Specificity values represent the proportion of a
gene’s total expression attributable to one cell type, with a value of 0 meaning a gene is not expressed in that cell type and a value of 1 meaning
that a gene is only expressed in that cell type. In both plots, cell types are coloured by the overall class they belong to (e.g. astrocyte, neuron,
oligodendrocyte, etc.).
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et al., 2019). This demonstrated significant enrichment of
genes associated with both presynaptic and postsynaptic
structures amongst those contained within all four modules
of interest (namely the substantia nigra ‘cyan’, putamen
‘cyan’, frontal cortex ‘lightyellow’ and white matter ‘blue’
modules). However, whereas the substantia nigra ‘cyan’ and
white matter ‘blue’ modules were more significantly enriched
for genes associated with presynaptic structures, the puta-
men ‘cyan’ and frontal cortex ‘lightyellow’ modules showed
more significant enrichments for genes associated with post-
synaptic structures (Fig. 4 and Supplementary Table 4).
Dystonia-linked modules in the
putamen and substantia nigra
represent expression signatures
unique to these tissues
We noted high overlaps amongst the DYT genes that
enriched in putamen, frontal cortex and white matter co-ex-
pression modules, with three DYT genes appearing in all
three of the relevant modules (ANO3, HPCA and
KCTD17), and a further four DYT genes appearing in at
least two of these modules (KCNA1, CACNA1A, PRRT2,
and SCN8A). As expected, given their well-defined role in
nigral dopamine synthesis, the genes clustering in the sub-
stantia nigra module were found to enrich exclusively in that
tissue. We extended this analysis by calculating module pres-
ervation statistics to assess how similar the four dystonia-
linked modules were to all co-expression modules identified
in the UKBEC dataset. Interestingly, we found that while the
white matter ‘blue’ and frontal cortex ‘lightyellow’ modules
showed strong evidence of preservation in other brain
regions, the substantia nigra and putamen ‘cyan’ modules
showed weak evidence of preservation (white matter ‘blue’
module, median Z summary statistic = 56.71; frontal cortex
‘lightyellow’ module, median Z summary statistic = 12.35;
putamen ‘cyan’ module, mean Z summary statistic = 5.93;
substantia nigra ‘cyan’ module, median Z summary statistic
= 3.95) (Fig. 5 and Supplementary Table 5). This indicates
that the dystonia-linked putamen and substantia nigra co-ex-
pression modules represent expression signatures specific to
these brain tissues. Furthermore, these results suggest that
while the DYT genes contained within these modules may
be widely expressed, they have gene-gene interactions that
are tissue-specific in nature.
Heritability of major-depressive
disorder, obsessive-compulsive
disorder and schizophrenia is
significantly enriched in dystonia-
linked modules
The identification of four UKBEC-derived co-expression
modules enriched for DYT genes (substantia nigra ‘cyan’,
putamen ‘cyan’, frontal cortex ‘lightyellow’ and white matter
‘blue’) provided an opportunity to investigate commonalities
in the underlying genetic architecture of dystonia and a
range of neuropsychiatric disorders noted to have a high
prevalence amongst individuals with the condition. Using
stratified LDSC we tested whether genes assigned to the
modules with high confidence (based on a module member-
ship of 5 0.5) significantly contributed to the common SNP
heritability of anxiety, major-depressive disorder, obsessive-
compulsive disorder, and schizophrenia. Given that in recent
Figure 3 Gene co-expression modules enriched for dystonia genes in the substantia nigra and putamen. The substantia nigra
‘cyan’ (A) and putamen ‘cyan’ (B) dystonia-linked UKBEC modules visualized using ‘bottom-up’ plots. In each case, the dystonia genes within the
modules are depicted as grey nodes with their most connected genes, as determined by the Topology Overlap Measure, depicted in cyan (to a
maximum of seven genes per seed). Node size reflects connectivity. Plots were generated using Cytoscape 3.5.1 and the Edge-weighted Spring
Embedded layout algorithm was used for rendering to a 2D canvas.
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years dystonia has been viewed primarily as a movement dis-
order with significant phenotypic overlap with Parkinson’s
disease (Shetty et al., 2019), we extended our analysis to in-
clude this condition.
Stratified LDSC demonstrated a significant enrichment of
obsessive-compulsive disorder heritability in the putamen
‘cyan’ module (obsessive-compulsive disorder, coefficient
P = 0.0014) and a significant enrichment of major-depressive
disorder and schizophrenia heritability in the white matter
‘blue’ module (major-depressive disorder, coefficient
P = 0.0014; schizophrenia, coefficient P = 3.54  10–5;
Fig. 6, Supplementary Table 6). Additionally, we observed
several nominal heritability enrichments, defined as those
enrichments in co-expression modules that did not pass the
Bonferroni cut-off (P5 0.05/(4  5)), but passed P5 0.05
(Supplementary Table 6). To assess the potential relevance
of these nominal enrichments, we tested if any could be
replicated in the GTEx-derived co-expression modules
enriched for DYT genes. We replicated the following find-
ings: first, an enrichment of schizophrenia heritability in the
putamen module (UKBEC putamen ‘cyan’, coefficient
P = 0.038; GTEx putamen ‘blue’, coefficient P = 6.70  10–7);
and second, an enrichment of Parkinson’s disease heritability
in the substantia nigra module (UKBEC substantia nigra
‘cyan’, coefficient P = 0.013; GTEx substantia nigra ‘darkor-
ange2’, coefficient P = 0.0027) (Supplementary Fig. 3 and
Supplementary Table 6).
Discussion
While there has been remarkable progress in our under-
standing of the genetic structure of dystonia, the anatomical,
cellular, and molecular basis remains unknown for most
genetic forms of dystonia, as does its genetic and biological
relationship to neuropsychiatric disorders. Using a systems
biology approach leveraging our current understanding of
the genetic basis of dystonia and neuropsychiatric disease,
we show that: (i) the expression of the currently known
DYT genes is significantly enriched in mouse adult nigral
Figure 4 Variable enrichment of genes associated with presynaptic and postsynaptic structures within dystonia-linked UKBEC
co-expression modules. Visualizations of the enrichment of SynGO ontology terms for synaptic location within the dystonia-linked UKBEC
modules (the substantia nigra ‘cyan’, putamen ‘cyan’, frontal cortex ‘lightyellow’ and white matter ‘blue’ modules) provided by the SynGO web re-
source (https://www.syngoportal.org/index.html). The hierarchical structure of SynGO terms is represented by concentric rings with the most
specific terms placed peripherally. The colour coding of the terms is based on the enrichment q-values. FCTX = frontal cortex; PUTM = puta-
men; SNIG = substantia nigra; WHMT = white matter.
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dopaminergic neurons and striatal MSNs and in human
dopaminergic neurons; (ii) multiple DYT genes are highly
co-expressed with each other in multiple brain regions rele-
vant to dystonia functional neuroanatomy, including the
substantia nigra, putamen, frontal cortex and white matter;
(iii) and finally, there is evidence of a genetic relationship be-
tween dystonia and complex neuropsychiatric diseases.
We found that the enrichment of DYT genes in mouse
and human dopaminergic neurons detected using EWCE
analysis was largely driven by genes that are involved in
various steps of dopamine synthesis and metabolism in nig-
ral dopaminergic neurons and when mutated are responsible
for DOPA-responsive dystonias (Ribot et al., 2019).
Similarly, WGCNA-based analyses showed that the same
Figure 5 Module preservation within UKBEC tissues containing dystonia-linked modules. Plot of module preservation for each
module within UKBEC tissues containing dystonia-linked modules. Module preservation, as denoted by the Z summary statistic, was determined
using a WGCNA-based preservation analysis applied across all ten UKBEC co-expression networks. Thus, each boxplot represents the preser-
vation of the named module within the labelled tissue across the remaining nine tissues. The black dashed lines indicate the threshold for strong
evidence of module preservation (Z summary statistic 4 10), as defined by Langfelder et al. (2011). Modules enriched with dystonia genes are
highlighted in red.
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genes clustered together in a single co-expression module
specific to the substantia nigra (‘cyan’ module). These results
are consistent with expectation, thus highlighting the reliabil-
ity of our hypothesis-free approach in identifying
disease-relevant cell types and tissue-specific gene-gene inter-
actions amongst DYT genes. With this in mind, we note that
none of the ‘non-DOPA-responsive’ DYT genes were highly
specific to dopaminergic neurons, nor did we find that any
co-clustered with the DOPA-responsive DYT genes in the
substantia nigra ‘cyan’ co-expression module. Together,
these results support the growing view that DOPA-respon-
sive dystonias should be considered a distinct subgroup not
only from a clinical perspective but also from a biological
point of view.
Other neuronal cell types highlighted by our EWCE- and
WGCNA-based analyses include MSNs, which constitute
95% of the cellular population of the putamen (Gerfen and
Surmeier, 2011). EWCE analysis showed that four DYT
genes, namely ADCY5, GNAL, ANO3, and KCTD17, had
the highest specificity of expression in MSNs, suggesting
they were the DYT genes driving the enrichment in MSNs.
Importantly, WGCNA results went beyond simply suggest-
ing a role for individual DYT genes within MSNs and indi-
cated a functional interaction of multiple DYT genes in a
single convergent pathway. Indeed, we observed eight DYT
genes, including three of four DYT genes with the highest
specificity in MSNs (ADCY5, ANO3, and KCTD17) and
five others that were not highlighted by EWCE analysis
(CACNA1A, SCN8A, KCNA1, PRRT2, HPCA), to be co-
expressed in the putamen ‘cyan’ module (the top module for
DYT gene enrichment across all tested co-expression mod-
ules). This co-expression module also contained several
established MSN-specific expression markers, including:
DRD1, DRD2 and ADORA2A, which encode the striatal
dopamine and adenosine receptors; and PPP1R1B, which
encodes DARPP-32, the universal marker of MSNs and part
of the signalling cascade downstream of dopaminergic and
adenosinergic receptor activation (Fienberg et al., 1998). In
summary, these results support a functional interaction and
biological convergence of multiple DYT genes in MSNs.
This biological convergence is noteworthy, given that the
function of several DYT genes found clustering in the puta-
men ‘cyan’ co-expression module (e.g. KCTD17, HPCA,
ANO3) is poorly characterized, especially in the context of
MSN biology.
To understand the biological function of DYT genes bet-
ter, all dystonia-linked co-expression modules were function-
ally annotated using Gene Ontology terms. This functional
annotation revealed that all four dystonia-linked co-expres-
sion modules were enriched for genes associated with synap-
tic function (in particular, genes associated with presynaptic
and postsynaptic structures), suggesting that DYT genes
found within these modules are also involved in synaptic
function. Notably, in the putamen-specific ‘cyan’ co-expres-
sion module the enrichment for genes associated with post-
synaptic structures yield a lower P-value than that for genes
associated with presynaptic structures. Given the central role
of MSNs in receiving and gating synaptic inputs from cor-
tical and thalamic glutamatergic neurons, this suggests that
disruption of postsynaptic function in MSNs through muta-
tions in multiple DYT genes may be important in dystonia
Figure 6 Enrichment of disease heritability within dys-
tonia-linked UKBEC co-expression modules. Stratified LDSC
using UKBEC co-expression modules. The black dashed lines indi-
cate the cut-off for Bonferroni significance [P5 0.05/(4  5)].
Bonferroni-significant results are marked with black borders.
Numerical results are reported in Supplementary Table 6. FCTX =
frontal cortex; MDD = major depressive disorder; OCD = obses-
sive compulsive disorder; PD = Parkinson’s disease; PUTM = puta-
men; SCZ = schizophrenia; SNIG = substantia nigra; WHMT =
white matter.
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pathogenesis. In support of this hypothesis are the following
observations: (i) abnormal plasticity and loss of synaptic
downscaling at cortico-striatal synapses has been shown to
be a dystonia endophenotype shared by different genetic ani-
mal models of dystonia (Martella et al., 2014; Calabresi
et al., 2016; Maltese et al., 2017; Zakirova et al., 2018; Yu-
Taeger et al., 2020); and (ii) ADCY5 and GNAL, two DYT
genes, form part of the signalling transduction machinery in
response to stimulation of dopaminergic and adenosinergic
signalling in MSNs (Herve, 2011; Goodchild et al., 2013;
Pelosi et al., 2017). Finally, evidence from genetic studies in
Drosophila support in vivo our findings implicating new
dystonia genes in postsynaptic signalling. Indeed, both
Insomniac and Nca (homologues of KCTD17 and HPCA,
respectively) were recently found to modulate sleep in
Drosophila, specifically through disruption of dopaminergic
postsynaptic pathways (Pfeiffenberger and Allada, 2012;
Chen et al., 2019; Kikuma et al., 2019).
These findings have significant clinical implications, par-
ticularly for classification of dystonias. Currently, genetic
forms of dystonia are primarily classified based on their clin-
ical presentation. However, there is significant variability
and pleiotropy in the clinical presentation of DYT mutation
carriers (Table 1), which makes the exact assignment of a
DYT mutation to a specific class of dystonia a hard task.
Additionally, it is debatable whether grouping patients based
on their clinical presentation correctly mirrors the underlying
neuroanatomical or biological substrates of different types of
dystonia. Importantly, the phenotypes associated with muta-
tions in the DYT genes enriched in the putamen ‘cyan’ mod-
ule belonged to different clinical subtypes of dystonia,
namely isolated dystonia (ANO3 and HPCA), combined
dystonia (KCTD17 and ADCY5), and paroxysmal dystonia
(KCNA1, CACNA1A, PRRT2 and SCN8A). Furthermore,
the putamen ‘cyan’ module contained several other genes
linked to monogenic hyperkinetic movement disorders,
including genes associated with inherited forms of chorea
(PDE2A, GPR88, HTT, VPS13A, JPH3) and dyskinetic epi-
leptic encephalopathies (GNB1, UNC13A, GRIN1, STX1B,
KNCQ2, and CACNA1B), strongly suggesting that similar
neuroanatomical and biological substrates underlie different
clinical subtypes of monogenic dystonias and other hyper-
kinetic movement disorders. This finding is highly consistent
with the growing appreciation that many neurogenetic disor-
ders are characterized by genetic pleiotropy and variable ex-
pressivity (Warman Chardon et al., 2015), and indicates
that the current system of dystonia classification based on
clinical presentation may not reflect the molecular structure
of the disease.
Clinically, variable expressivity may also extend to neuro-
psychiatric symptoms often observed in individuals with
dystonia. In support of this notion, we showed that the co-
expression modules enriched for DYT genes also enriched
for the heritability of several neuropsychiatric disorders,
including major-depressive disorder, obsessive-compulsive
disorder and schizophrenia. These results reinforce the con-
cept that neuropsychiatric disorders commonly observed in
dystonic patients, such as major-depressive disorder and ob-
sessive-compulsive disorder, are intrinsic to the neurobiology
of dystonia. More specifically, these findings suggest that
psychiatric symptoms are not merely a reaction to the dis-
ability arising from dystonia, but rather, the underlying mo-
lecular pathophysiology of dystonia increases a patient’s risk
of developing psychiatric symptoms. At the same time, dys-
function of overlapping molecular pathways in the striatum
may underlie the growing appreciation of movement disor-
ders, including dystonia and other hyperkinesias, affecting
drug-naı̈ve schizophrenic patients (Peralta et al., 2010;
Walther and Strik, 2012; Compton et al., 2015).
Notably, integration of GWAS-identified risk variants for
obsessive-compulsive disorder and schizophrenia together
with recent transcriptomic analyses have implicated MSNs
in the neurobiology of these neuropsychiatric diseases (Skene
et al., 2018; Yilmaz et al., 2018). We too observed an en-
richment of obsessive-compulsive disorder and schizophrenia
heritability in the MSN-related putamen modules, suggesting
that dysfunction of MSN synaptic activity, resulting from
different types of genetic insult, may represent an overlap in
the biology of dystonia and these neuropsychiatric condi-
tions. Glutamatergic pyramidal neurons have also been
shown to be central to the aetiology of schizophrenia, and
the ‘blue’ white-matter module, which enriched for markers
of pyramidal neurons, also enriched for DYT genes and
schizophrenia heritability (Skene et al., 2018). Similarly, the
enrichment of major-depressive disorder heritability
observed in the ‘blue’ white matter module suggests that syn-
aptic dysfunction induced by dysregulation of dystonia genes
and their interactors in glutamatergic pyramidal neurons
might also underpin the high risk and occurrence of depres-
sion in dystonia patients. Altogether, these findings appear
to support the concept that the same genetic disruption
could operate across multiple brain regions and produce dif-
ferent clinical effects (i.e. dystonia versus predisposition to
psychiatric symptoms), depending on the tissue-specific
gene-gene interactions present.
Finally, we extended our analysis to Parkinson’s disease, a
movement disorder primarily caused by dysfunction of nig-
ral dopaminergic neurons and with significant clinical over-
lap with dystonia (Shetty et al., 2019). We observed
enrichment of Parkinson’s disease heritability in the substan-
tia nigra modules, UKBEC ‘cyan’ and GTEx ‘darkorange2’,
also enriched for DOPA-responsive DYT genes, suggesting
an overlap that goes beyond clinical features and extends to
molecular mechanisms. In support of this finding, rare and
common variants in GCH1, the most common genetic cause
of DOPA-responsive dystonia, have also been shown to in-
crease the risk of Parkinson’s disease (Mencacci et al., 2014;
Nalls et al., 2019). We also noted that these modules con-
tained SNCA, the gene encoding alpha-synuclein. This ob-
servation may provide novel insights into the relationship
between Parkinson’s disease, dystonia and dopamine metab-
olism, especially considering the emerging role of alpha-syn-
uclein in synaptic biology and neurotransmitter release
(Sulzer and Edwards, 2019).
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Limitations
While our analysis highlights the contribution of certain
brain regions, cell-types and biological functions in dystonia
pathogenesis, we recognize its limitations. First and fore-
most, this study depends on the quality and completeness of
the genetic data we use. As we can only analyse known
DYT genes to identify cell types and co-expression modules
of interest, our findings could change with the identification
of additional disease-associated genes. This limitation might
explain our failure to detect an enrichment of DYT genes in
other dystonia-associated brain regions (e.g. cerebellum).
Similarly, limitations in GWAS power (in particular, for
anxiety and obsessive-compulsive disorder) limit our ability
to assess enrichments in heritability within specific gene sets.
Second, this study is limited by the availability of high qual-
ity, region and cell-specific gene expression data. Because of
its completeness, we use mouse-derived cellular profiles to
assess cell specificity of gene expression of the DYT genes.
While we were able to replicate our enrichment of DYT
genes in human dopaminergic neurons, we appreciate there
may still be species differences. In addition, the co-expression
networks analysed are generated through the analysis of a
set of adult-derived brain regions, limiting the spatial reso-
lution, and more importantly, preventing the analysis of po-
tentially critical developmental windows. Hence, we may be
unable to detect disease-relevant genetic interactions of DYT
genes that are likely to generate dystonia through a funda-
mental role during brain development, such as TOR1A,
THAP1 and KMT2B (Vasudevan et al., 2006; Zhao et al.,
2013; Faundes et al., 2018). Further, this could represent
one of the reasons why we could not replicate previous
observations implicating TOR1A and THAP1 in dopamin-
ergic signalling (Balcioglu et al., 2007; Carbon et al., 2009;
Napolitano et al., 2010; Frederick et al., 2019). Finally,
given that we do not have access to significant quantities of
brain transcriptomic data from individuals with genetic
forms of dystonia, we assume that DYT genes operate
through a loss of their normal function rather than through
novel gains of function.
Conclusion
In summary, this work enabled the unbiased identification
of brain region-specific modules of biologically related genes
and provided insights on cell-specific molecular signatures
relevant to dystonia. We find that multiple DYT genes are
functionally related in the adult human brain and likely con-
tribute to modulation of synaptic signalling in striatal
MSNs, adult dopaminergic neurons and frontal cortical neu-
rons. While the exact mechanism of each individual DYT
gene’s participation in this physiological process remains un-
known, these results demonstrate a functional convergence
of DYT genes linked to different phenotypic presentations
and apparently unrelated cellular processes. These results
bear significance for the treatment of dystonia, as future
therapeutic approaches may target shared pathophysiologic-
al abnormalities, as opposed to symptoms. Finally, we dem-
onstrate a genetic relationship between dystonia and several
neuropsychiatric disorders, suggesting that disruption of gen-
etic networks linked to dystonia pathogenesis in discrete
brain regions may represent the neurobiological basis for the
phenotypic overlap between dystonia and neuropsychiatric
disorders.
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